Saltar al contenido
PivotalWire
Domingo 22 nov 2026SEC · NASDAQ biomédico

Calendario›PTGX›Rusfertide · VERIFY

Rusfertide · VERIFY

Ensayo de Protagonist Therapeutics, Inc en Policitemia Vera.

Más ensayos de: Policitemia vera.

Fase
Fase 3
Estado
En marcha, sin reclutar
Participantes
293
previstos
Centros
184
Fin del objetivo primario
feb 2025
fecha real

Título oficial en el registro (en inglés): A Study of Rusfertide in Adults With Polycythemia Vera (PV)

Qué significa cada fase y cada estado.

Estudio de intervención, aleatorizado, triple ciego. Comenzó en abr 2022.

De principio a fin

  1. Empieza el ensayo (abr 2022)
  2. Lectura de resultados feb 2025 (real)
  3. Hoy

Los cambios los anota PivotalWire desde agosto de 2026; lo anterior no lo tenemos. El historial completo, versión a versión, está en ClinicalTrials.gov.

Qué mide

Proporcion de sujetos que logran una respuesta que reciben rusfertida comparado con placebo. (From Weeks 20 to 32) (del registro, en inglés)

Qué se prueba

Se evalúan la seguridad y eficacia de rusfertide en pacientes con policitemia vera, en el control del hematocrito y la mejora de síntomas.

Lo que dice el documentoevaluate the safety and efficacy of rusfertide in subjects with polycythemia vera (PV) in maintaining hematocrit control and in improving symptoms of PV.

Traducción automática (claude-sonnet-5). Lo comprobado es la cita: está literal en el documento y sus cifras cuadran con las de la frase. Todavía no la ha leído una persona.

Cómo lo describe el promotor

En el documentoEn inglés, del registroPolycythemia vera (PV) is a long-term condition in which the bone marrow makes too many red blood cells (RBCs). Bone marrow is the soft tissue inside the large bones where blood cells are made. When there are too many RBCs, called erythrocytosis, the blood can become thicker and move less easily through blood vessels and organs. This can raise the risk of blood clots (thrombosis) in veins or arteries. Sometimes, these clots can be life-threatening and may cause a stroke or heart attack. Treatment aims to keep the percentage of RBCs in the blood (hematocrit) in a safe range. For adults with PV, this means keeping the hematocrit below 45%. This helps lower the blood thickness and the risk of thrombosis. PV can also be linked to low iron levels (iron deficiency), because the body uses iron to make more RBCs. Many people with PV are treated with blood removal (phlebotomy) to lower RBC levels in the blood. This can worsen the iron deficiency, because each blood removal also takes iron out of the body. Rusfertide is a medicine that lowers the amount of iron available in the blood. It works like hepcidin, a natural hormone that helps control iron levels in the body. By limiting iron available for RBC production, rusfertide may help keep hematocrit below 45% and may improve symptoms. It may also reduce, or even remove, the need for phlebotomy in people. The main aim of this study is to check how well rusfertide works compared with placebo to lower the number of phlebotomies. A placebo looks like rusfertide but does not have any medicine in it. Other aims are to learn how safe rusfertide is compared with placebo and to understand how well it works to reduce the need for phlebotomy and to keep hematocrit levels under control. The study also wants to learn how rusfertide moves through the body (pharmacokinetics) and how it affects the body (pharmacodynamics or PD). This study has 4 parts that follow each other: * In part 1a, participants will receive either rusfertide or placebo. * In part 1b, all participants will receive rusfertide. * In part 2, participants can continue to receive rusfertide if they benefit from treatment with rusfertide. * Part 3 will include participants who finish Part 2 and still benefit from rusfertide. During the study, participants will visit the study clinical several times at fixed timepoints.

Más ensayos de PTGX

EnsayoFaseEstadoLectura de resultados
Open-label rusfertide · THRIVEFase 3En marcha, sin reclutarabr 2026 (prevista, ya pasada: sin actualizar en el registro)
PN-881 Oral SolutionFase 1Completadojul 2026 (real)
PTG-300 · PACIFICFase 2Completadomar 2023 (real)
PN-943Fase 2Completadofeb 2023 (real)
PTG-300Fase 2Completadofeb 2023 (real)
PN-232Fase 1Completadodic 2021 (real)

Todos los de PTGX, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT05210790), actualizada en sep 2026.